ReviewVision research2008
Nanoparticle applications in ocular gene therapy.
Review in Vision research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Advances in gene transfer technologies: comparing viral and non-viral vectors for therapeutic applications.3 Biotech · 2026Review
- Review
- The Contribution of Nanomedicine in Ocular Oncology.Cancers · 2025Review
- Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.Journal of nanobiotechnology · 2023Review
- Application of biomaterials and nanotechnology in corneal tissue engineering.The Journal of international medical research · 2023Review
- Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities.Journal of nanobiotechnology · 2022Review
- Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Novel insights into gene therapy in the cornea.Experimental eye research · 2021Review
- Ophthalmic Administration of a DNA Plasmid Harboring the Murine Tph2 Gene: Evidence of Recombinant Tph2-FLAG in Brain Structures.Molecular biotechnology · 2020Article
- Nanoparticles for drug delivery to the anterior segment of the eye.Advanced drug delivery reviews · 2017Review
- Enhanced delivery of biodegradable mPEG-PLGA-PLL nanoparticles loading Cy3-labelled PDGF-BB siRNA by UTMD to rat retina.Journal of biosciences · 2017Article
- Advanced drug delivery and targeting technologies for the ocular diseases.BioImpacts : BI · 2016Review
- Nanomedicine in the application of uveal melanoma.International journal of ophthalmology · 2016Review
- Nanomedicine approaches for corneal diseases.Journal of functional biomaterials · 2015Review
- Article
- Nanocarriers of nanotechnology in retinal diseases.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society · 2014Review
- Corneal gene therapy: basic science and translational perspective.The ocular surface · 2013Review
- A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model.Gene therapy · 2013Article
- Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles.Colloid and polymer science · 2013Article
- Transfection efficiency of chitosan and thiolated chitosan in retinal pigment epithelium cells: A comparative study.Journal of pharmacy & bioallied sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The use of nanoparticles as carriers for the delivery of therapeutic materials to target tissues has became popular in recent years and has demonstrated great potentials for the treatments of a wide range of diseases. In this review, we summarize the advantages of nanotechnology as a common gene delivery strategy with emphasis on ocular therapy. Particular attention is paid to the CK30-PEG compacted DNA nanoparticles that have been successfully tested in the eye, lung, and brain. These particles resulted in higher transfection efficiency and longer duration of expression than other non-viral vectors without any toxicity or other side effects. They have been safely used clinically and are efficient for a broad range of gene therapy applications. The review also discusses mechanisms of nanoparticle uptake and internalization by cells, obstacles and limitations to the use of this technology, as well as novel methodologies to optimize nanoparticle driven gene expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.